EU approves Novo Nordisk's Levemir for use with oral anti-diabetic drugs |
|
|
|
Published
:
Thu, 01 Mar 2007 12:34
|
COPENHAGEN (AFX) - Novo Nordisk AS said the European Commission has approved its insulin analogue Levemir for once-daily use in combination with oral anti-diabetic drugs (OADs).'The new approval of Levemir... provides a new treatment option for people with type 2 diabetes who have difficulties in maintaining acceptable blood glucose levels when treated with OADs alone,' Novo Nordisk said.gustav.sandstrom@thomson.comgs/amCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1796.52 |
-49.20 (
-2.70 %)
|
| SYMBOL (
2009-07-03 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
1625.00 |
+15.00 (
0.93 %)
|
| SYMBOL (
2009-07-02 )
|
| LAST |
CHANGE
|
|
INTEL CP
(
4:00pm ) |
|
16.72 |
-0.32 (
-1.90 %)
|
| SYMBOL (
2009-07-02 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Danish shares AFX market data at 9.30 am - Novo Nordisk falls ahead of FY result 